Vytrus Biotech SA
MAD:VYT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (6.1), the stock would be worth €5.62 (71% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 21.2 | €19.6 |
0%
|
| 3-Year Average | 6.1 | €5.62 |
-71%
|
| 5-Year Average | 6.1 | €5.62 |
-71%
|
| Industry Average | 2.8 | €2.57 |
-87%
|
| Country Average | 1.8 | €1.65 |
-92%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
€89m
|
/ |
Jul 2025
€6.9m
|
= |
|
|
€89m
|
/ |
Dec 2025
€7.1m
|
= |
|
|
€89m
|
/ |
Dec 2026
€8.5m
|
= |
|
|
€89m
|
/ |
Dec 2027
€10.2m
|
= |
|
|
€89m
|
/ |
Dec 2028
€15.4m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
|
Vytrus Biotech SA
MAD:VYT
|
149m EUR | 21.2 | 76.3 | |
| FR |
|
L'Oreal SA
PAR:OR
|
199.5B EUR | 4.5 | 32.6 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
92.2B GBP | 2.6 | 11.2 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.5T INR | 8.3 | 37.4 | |
| UK |
|
HALEON PLC
LSE:HLN
|
31.2B GBP | 3.4 | 18.7 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
28B USD | 2.2 | -157.1 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
15.8B EUR | 1.4 | 16.9 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 1.5 | 22.4 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.1T INR | 7.4 | 60.9 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | 855.7 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
801.7B INR | 5.8 | 43.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.8 |
| 70th Percentile | 4.4 |
| Max | 678.5 |
Other Multiples
Vytrus Biotech SA
Glance View
Vytrus Biotech SA is a biotechnology company, which engages in the development of cosmetic active ingredients from plant stem cell technology. The company is headquartered in Terrassa, Barcelona and currently employs 28 full-time employees. The company went IPO on 2022-03-24. The firm develops high added value natural active ingredients on an industrial scale and provides ingredients and recombinant proteins for its use in the cosmetics and pharmaceutical sectors. The Company’s technology is based on using plant cell cultures to produce bioactive molecules. The firm obtains plant cells, known as Plant Stem Cell technology, which is applicable for cosmetics.
